Head-to-head · WeighScore
Contour Health vs LillyDirect Foundayo
The verdict
LillyDirect Foundayo takes it — 67.2/100 to 66.8/100, but only just.
LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. Contour Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Contour Health | LillyDirect Foundayo |
|---|---|---|
| WeighScore | 66.8/100 | 67.2/100 |
| Grade | C | C |
| Scorecard rank | #177 | #165 |
| Semaglutide | $160/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $300/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #177 · C
Strengths
- Free medical consultation — no charge to talk with a provider before starting
- Pay-per-vial pricing with no long-term subscription commitment required to participate
- Names its compounding pharmacy partner (Strive Pharmacy, 503A accredited) — a real transparency signal
- LegitScript badge links to a genuine, working LegitScript verification checker for the domain
- Board-certified Medical Director and named nurse-practitioner care team, not anonymous providers
Where it loses points
- State availability list is not published — Terms of Service only says "certain states"
- All product purchases are non-refundable per Terms of Service
- Compounded injectable only — no oral option, no brand-name Wegovy/Zepbound/Ozempic/Mounjaro
- Terms of Service also describe an optional subscription tier with a 3-month minimum, despite marketing emphasizing "no subscriptions"
- No insurance, Medicare, or Medicaid accepted — cash-pay or HSA/FSA only
Graded #165 · C
Strengths
- Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- Direct from manufacturer — no compounding, no third-party reseller
- Daily oral pill, no injections, no refrigeration
- Available in all 50 states
Where it loses points
- Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- Strict empty-stomach 30-minute window may be hard for some patients to follow
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.